Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

Chronic activation of the Bruton’s tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark of many B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Ibrutinib, an FDA approved, orally administered BTK inhibitor,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Kapoor, Isha, Li, Yue, Sharma, Arishya, Zhu, Huayuan, Bodo, Juraj, Xu, Wei, Hsi, Eric D., Hill, Brian T., Almasan, Alexandru
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6892912/
https://ncbi.nlm.nih.gov/pubmed/31801949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-2158-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars